193 Impact of vaginal cuff brachytherapy in operated patients with high risk early stage cervical cancer

ObjectivesTo evaluate local control and survival of high risk cervical cancer patients submitted or not to vaginal cuff brachytherapy in the post-operative setting.MethodsRetrospective cohort of patients treated from 2010 to 2017. Patients were eligible if they had confirmed histological diagnosis o...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gynecological cancer Vol. 29; no. Suppl 3; pp. A84 - A85
Main Authors Mauro, G, Kleine Truffa, R, Silva Cabral Severino, S, Carvalho de Andrade, H
Format Journal Article
LanguageEnglish
Published Oxford by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology 01.09.2019
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ObjectivesTo evaluate local control and survival of high risk cervical cancer patients submitted or not to vaginal cuff brachytherapy in the post-operative setting.MethodsRetrospective cohort of patients treated from 2010 to 2017. Patients were eligible if they had confirmed histological diagnosis of cervical cancer treated with surgery and adjuvant radiotherapy with or without chemotherapy. Vaginal cuff brachytherapy (VCB) was indicated according to the radiation oncologist discretion.ResultsSeventy-nine patients were selected, with a median age at diagnosis of 47.5 years (26–77). Brachytherapy was delivered in 59 (74.7%). There were no significant differences between the VCB and the no-VCB groups. A total of 13 (16.5%) patients presented one or more events, 5 (25%) and 8 (13.5%) events in the no-VCB and VCB group, respectively. Most recurrences were pelvic and/or vaginal: 7/20 (35%) in the no-VCB group and 9/59 (10.2%) in the VCB group. There were 8 systemic relapses with 8 deaths. With a median follow-up of 45 months, median overall and disease-free survival were, respectively, 85.1 and 83.8 months. No variables were correlated with overall survival. The only factor positively correlated to disease-free survival was VCB, with a mean of 86.9 and 68.4 months for patients that did and did not receive it, respectively (p=0.043). Vaginal recurrence was lower in the brachytherapy group, but with no significance (p=0.065).ConclusionsVCB was associated with a reduced recurrence rate in the post-operative setting of high-risk early stage cervical cancer patients.
ISSN:1048-891X
1525-1438
DOI:10.1136/ijgc-2019-IGCS.193